Abstract | INTRODUCTION AND HYPOTHESIS: Risk of pelvic floor disorders increases after menopause and may be linked to estrogen deficiency. We aimed to systematically and critically assess the literature on vaginal estrogen in the management of pelvic floor disorders in postmenopausal women and provide evidence-based clinical practice guidelines. METHODS: MEDLINE and Cochrane databases were searched from inception to July 2014 for randomized controlled trials of commercially available vaginal estrogen products compared with placebo, no treatment, or any medication for overactive bladder or urinary incontinence. We double-screened 1,805 abstracts and identified 12 eligible papers. Studies were extracted for participant information, intervention, comparator, efficacy outcomes, and adverse events, and they were individually and collectively assessed for methodological quality and strength of evidence. RESULTS: CONCLUSION:
|
Authors | David D Rahn, Renée M Ward, Tatiana V Sanses, Cassandra Carberry, Mamta M Mamik, Kate V Meriwether, Cedric K Olivera, Husam Abed, Ethan M Balk, Miles Murphy, Society of Gynecologic Surgeons Systematic Review Group |
Journal | International urogynecology journal
(Int Urogynecol J)
Vol. 26
Issue 1
Pg. 3-13
(Jan 2015)
ISSN: 1433-3023 [Electronic] England |
PMID | 25392183
(Publication Type: Journal Article, Practice Guideline, Review, Systematic Review)
|
Chemical References |
|
Topics |
- Administration, Intravaginal
- Estrogens
(administration & dosage)
- Female
- Humans
- Pelvic Floor Disorders
(drug therapy, surgery)
|